PI3K 抑制剂抗肿瘤临床研究进展

磷脂酰肌醇-3-激酶 (PI3K) 是一种胞内磷脂酰肌醇激酶,在介导细胞生长、发育、分裂、分化和凋亡等过程中发挥重要作用,因此 PI3K 抑制剂的开发已成为当前抗癌新药研究的热点之一。目前已有多个 PI3K 抑制剂进入临床研究阶段或已上市,其单用或与其他药物联 用的疗效和安全性有待进一步临床验证。综述 PI3K 抑制剂作为抗肿瘤药物的临床研究进展,为其进一步研究与应用提供参考。

Advances in the Clinical Development of PI3K Inhibitors asAnticancer Agents

Phosphatidylinositol 3-kinase (PI3K) is an intracellular phosphatidylinositol kinase and plays a very important role in the processes of cell growth, development, division, differentiation and apoptosis. Therefore, the development of PI3K inhibitor for cancer chemotherapy is becoming a hot spot of present research. Currently, there are many PI3K inhibitors under clinical development or approved for marketing. The ef cacy and safety of PI3K inhibitors as mono-therapy or in combined therapy still need further clinical evaluation. This paper reviewed the clinical development of phosphatidylinositol 3-kinase inhibitors as anticancer agents, so as to provide references for further investigation and application of PI3K inhibitors.